Skip to main content
. 2021 Jun;12(3):1180–1190. doi: 10.21037/jgo-21-283

Figure 1.

Figure 1

The expression of PADI1 and prognosis in PAAD patients. TCGA database was searched to investigate (A) the expression of PADI1 in tumor and normal tissues, and (B) the effects of PADI1 on the survival prognosis of PAAD patients. ***, P<0.001, compared with normal. (C) A quantitative real-time PCR and (D) western-blot analysis were applied to determine the expression of PADI1 mRNA and protein levels, respectively, in five PAAD cell lines (i.e., CFPAC-1, PANC-1, PL45, Bxpc-3, and HPAC) and the human pancreatic cell line, hTERT-HPNE. ***, P<0.001, compared with the hTERT-HPNE. (E) PADI1 was observed using immunofluorescence (400×) in PAAD cell lines and hTERT-HPNE. PADI1, peptidylarginine deiminase 1; PAAD, pancreatic ductal adenocarcinoma; TCGA, The Cancer Genome Atlas; PCR, polymerase chain reaction; mRNA, messenger RNA.